Price
CHART BY
Frequently asked questions
What is CytomX's market capitalization?
The market capitalization of CytomX is $810.58M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for CytomX?
CytomX's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.457. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for CytomX's stock?
Currently, 8 analysts cover CytomX's stock, with a consensus target price of $12.25. Analyst ratings provide insights into the stock's expected performance.
What is CytomX's revenue over the trailing twelve months?
Over the trailing twelve months, CytomX reported a revenue of $18.30M.
What is the EBITDA for CytomX?
CytomX's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$86.31M. EBITDA measures the company's overall financial performance.
What is the free cash flow of CytomX?
CytomX has a free cash flow of -$82.48M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does CytomX have, and what sector and industry does it belong to?
CytomX employs approximately 69 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of CytomX's shares?
The free float of CytomX is 190.34M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $810.58M
- EPS (TTM)
- -$0.457
- Free Float
- 190.34M
- Revenue (TTM)
- $18.30M
- EBITDA (TTM)
- -$86.31M
- Free Cashflow (TTM)
- -$82.48M
Pricing
- 1D span
- $3.536$3.736
- 52W span
- $1.90$8.20
Analyst Ratings
The price target is $12.25 and the stock is covered by 8 analysts.
Buy
8
Hold
0
Sell
0
Information
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
- Employees
- 69
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- CTMX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet